

1 Page 1/2

2 PHARMACOPOEIAL DISCUSSION GROUP  
3 SIGN-OFF DOCUMENT

4 **G14: CHARACTERISATION OF CRYSTALLINE AND PARTIALLY CRYSTALLINE**  
5 **SOLIDS BY X-RAY POWDER DIFFRACTION (XRPD)**

6 (CP = EP)

7 *It is understood that sign-off covers the technical content of the draft and each party will*  
8 *adapt it as necessary to conform to the usual presentation of the pharmacopoeia in question;*  
9 *such adaptation includes stipulation of the particular pharmacopoeia's reference materials*  
10 *and general chapters.*

## 11 - Harmonised Provisions

Provision	EP	JP	USP
PRINCIPLE	+	+	+
INSTRUMENT	+	+	+
SPECIMEN PREPARATION	+	+	+
SPECIMEN MOUNTING	+	-	+
CONTROL OF INSTRUMENT PERFORMANCE	+	+	+
QUALITATIVE PHASE ANALYSIS	+	+	+
QUANTITATIVE PHASE ANALYSIS	+	+	+
ESTIMATE OF THE AMORPHOUS AND CRYSTALLINE FRACTIONS	+	+	+
SINGLE CRYSTAL STRUCTURE	+	+	+

13 Legend

14 +: will adopt and implement

15 -: will not stipulate

## 16 - Non-harmonised provisions

## 17 Reagents and reference materials

18 Each pharmacopoeia will adapt the text to take account of local reference materials and  
19 reagent specifications.

20

25/10/07


2 PHARMACOPOEIAL DISCUSSION GROUP

3 SIGN-OFF DOCUMENT

4 G14: CHARACTERISATION OF CRYSTALLINE AND PARTIALLY CRYSTALLINE  
5 SOLIDS BY X-RAY POWDER DIFFRACTION (XRPD)

6 (CP = EP)  
7


8 **European Pharmacopoeia**

10	Signature	Name	Date
11		LEFTEL	30.10.2007
12			
13			

14 **Japanese Pharmacopoeia**

16	Signature	Name	Date
17		Toshiro Nakagaki	Oct 30, 2007
18			
19			

20 **United States Pharmacopeia**

21	Signature	Name	Date
22		DARRA R. FERRER	30 Oct, 2007